ACOR News and Press, Acorda Therapeutics Inc. From 05/23/22

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Acorda Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Start Time: 16:30 End Time: 17:02 Acorda Therapeutics, Inc. (ACOR) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 PM ET Company Participants Ron Cohen - Founder, President and CEO Mike Gesser - CFO Tierney Saccavino - EVP, Corporate Communications Conference Call Participants Muzamil Sa...

The commercial-stage biotech, Acorda Therapeutics (NASDAQ:ACOR), and South American pharma company, Biopas Laboratories announced an agreement on Wednesday to commercialize Acorda’s (ACOR) Parkinson's disease therapy Inbrija in certain Latin American countries. Accordingly, Biopas will...

Acorda Therapeutics press release (NASDAQ:ACOR): Q1 Non-GAAP EPS of -$1.66. Revenue of $22.53M (-21.9% Y/Y). INBRIJA (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 AMPYRA (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decr...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA ® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic moto...

INBRIJA ® (levodopa inhalation powder) Q1 2022 net revenue of $3.7 million; 26% decrease from Q1 2021 AMPYRA ® (dalfampridine) Q1 2022 net revenue of $14.9 million; 27% decrease from Q1 2021 2022 AMPYRA net sales guidance reiterated at $68-$78 million ...

ACOR, ADMA, APP, ASM, ASND, ASYS, ATCO, BAK, BMBL, BROS, BYND, CLPT, CLSD, CPA, CPNG, CYCC, DIS, DOX, ENVX, FLNC, FOSL, FSM, GAIN, GBDC, ICAD, KGC, LGO, LKCO, LTBR, MBII, METC, MFC, MQ, MRAM, MYO, NEON, NOAH, OCX, ONTX, OR, OTRK, PAAS, PAYS, PSTL, OTCPK:PWCDF, RIVN, SAND, SCM, SCTL, SLF, SMTS...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET. To participate in the Webcast, please use the following pre-registration link: https://e...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...